As of 2024-12-13, the Intrinsic Value of Arecor Therapeutics PLC (AREC.L) is (1,100.92) GBP. This AREC.L valuation is based on the model Discounted Cash Flows (Growth Exit 5Y). With the current market price of 76.50 GBP, the upside of Arecor Therapeutics PLC is -1,539.10%.
The range of the Intrinsic Value is (1,515.57) - (870.63) GBP
Note: result may not be accurate due to the invalid valuation result of DCF model.
| Range | Selected | Upside | |
| a | |||
| DCF (Growth 5y) | (1,515.57) - (870.63) | (1,100.92) | -1539.1% |
| DCF (Growth 10y) | (1,980.40) - (3,582.11) | (2,553.59) | -3438.0% |
| DCF (EBITDA 5y) | (898.05) - (1,257.93) | (1,234.50) | -123450.0% |
| DCF (EBITDA 10y) | (2,057.88) - (3,095.62) | (1,234.50) | -123450.0% |
| Fair Value | -114.76 - -114.76 | -114.76 | -250.02% |
| EV/EBITDA | (414.61) - (234.26) | (365.51) | -577.8% |
| EPV | (141.39) - (180.85) | (161.12) | -310.6% |
| DDM - Stable | (142.45) - (330.53) | (236.49) | -409.1% |
| DDM - Multi | (566.60) - (1,039.57) | (735.26) | -1061.1% |
| Market Cap (mil) | 28.88 |
| Beta | 0.62 |
| Outstanding shares (mil) | 0.38 |
| Enterprise Value (mil) | 26.63 |
| Market risk premium | 5.98% |
| Cost of Equity | 12.76% |
| Cost of Debt | 7.23% |
| WACC | 12.69% |